Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Condition: End Stage Renal Disease on Dialysis Interventions: Drug: Empagliflozin 25 mg vs Placebo; Drug: Empagliflozin 10 MG Sponsors: Yale University; Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials